Hanmi wins gemicitabine patent

Hanmi Pharm announced on April it acquired a Korean patent related to a core technology of producing gemcitabine intermediate, entitled 1--halo-2,2-difluoro-2-deoxy-D-ribofuranose derivative and its manufacturing method.

Gemcitabine is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, and breast cancer. It is being investigated for use in esophageal cancer, and is us...